Happy Belly Food Group Appoints Former Boston Pizza Vice President of Finance and Business Technology as their Executive Vice President of Finance as Franchising Growth Continues to Accelerate

Toronto, Ontario–(Newsfile Corp. – January 6, 2026) – Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) (“Happy Belly” or the “Company“), a leading consolidator of emerging restaurant brands, is pleased to announce the appointment of Ian Thomas as Executive Vice President of Finance, effective immediately. Mr. Thomas joins Happy Belly with more than 25 […]

Southern Cross Gold Drills 12.2 m @ 32.4 g/t Gold at Golden Dyke

Vancouver, British Columbia and Melbourne, Australia–(Newsfile Corp. – January 6, 2026) – Southern Cross Gold Consolidated Ltd (TSX: SXGC) (ASX: SX2) (OTCQX: SXGCF) (FSE: MV3) (“SXGC”, “SX2” or the “Company”) announces results from four drillholes from the 100%-owned Sunday Creek Gold-Antimony Project in Victoria (Figures 1 to 5). Best results included 12.2 m @ 32.4 g/t Au from

Lithium Argentina Announces 2025 Production Results for Cauchari-Olaroz and Leadership Updates

(TSX:LAR),(NYSE:LAR), ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company“) (TSX: LAR) (NYSE: LAR) today announced preliminary 2025 operational results for the Cauchari-Olaroz lithium brine operation (“Cauchari-Olaroz“) in Jujuy, Argentina. Cauchari-Olaroz delivered strong and consistent operating performance through 2025, achieving production at the high end of annual guidance

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

(NasdaqGM:APGE), Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients – Suppression of FeNO through 32 weeks for patients with available follow up – Results reinforce continued development in asthma testing every 3- or 6-month dosing

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

(NASDAQ:ACON),(NASDAQ:ACONW), Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q

McEwen Inc. and Canadian Gold Corp. Announce Closing of Arrangement

(TSX:MUX),(NYSE:MUX),(TSX-V:CGC), TORONTO and FLIN FLON, Manitoba, Jan. 06, 2026 (GLOBE NEWSWIRE) — McEwen Inc. (“McEwen“) (NYSE/TSX:MUX) and Canadian Gold Corp. (“Canadian Gold“) (TSX-V:CGC) are pleased to announce the completion of the previously announced business combination between McEwen and Canadian Gold by way of statutory plan of arrangement (the “Arrangement“). Shareholders of Canadian Gold approved the

G2 Goldfields Drilling Continues to Expand High-Grade Gold Resource at OKO

(TSX:GTWO),(OTC US:GUYGF),(Other OTC:GUYGF), Drilling intersects new gold mineralisation south of existing pit shells, including a high-grade intercept of 39.3 g/t Au over 2.7m and 2.1 g/t Au over 30m. Significant gold mineralisation intercepted down-plunge of current gold resource including 4.0 g/t Au over 23.5m within 2.4 g/t Au over 50m. Major drill program initiated with

Radware Doubles Global Cloud Security Capacity

(NASDAQ:RDWR), Cloud security service centers now equipped to mitigate up to 30 Tbps of attack volume Latest generation of DefensePro(R) X, Radware's industry-leading DDoS mitigation platform allows for enhanced precision automation, speed and complex attack protection MAHWAH, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) — Radware(R) (NASDAQ: RDWR), a global leader in application security and delivery

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook GlobeNewswire January 06, 2026 Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2

Lithium Argentina Announces 2025 Production Results for Cauchari-Olaroz and Leadership Updates

Lithium Argentina Announces 2025 Production Results for Cauchari-Olaroz and Leadership Updates GlobeNewswire January 06, 2026 ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company“) (TSX: LAR) (NYSE: LAR) today announced preliminary 2025 operational results for the Cauchari-Olaroz lithium brine operation (“Cauchari-Olaroz“) in Jujuy, Argentina. Cauchari-Olaroz delivered strong and

Scroll to Top